Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock
August 08, 2019 22:23 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
August 07, 2019 16:25 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®
August 06, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Reports Second Quarter 2019 Financial Results
August 02, 2019 07:00 ET
|
Stemline Therapeutics, Inc.
Net revenue for ELZONRIS® was $13.0 million for the second quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline...
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019
July 29, 2019 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting
July 08, 2019 17:50 ET
|
Stemline Therapeutics, Inc.
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
June 17, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15
June 13, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program
June 03, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress
May 20, 2019 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...